mov10b.1 Antibody

What is MOV10 and what are its key cellular functions?

MOV10 (Moloney leukemia virus 10, homolog) is a 5' to 3' RNA helicase belonging to the DNA2/NAM7 helicase family and SDE3 subfamily . This interferon-inducible protein is involved in numerous cellular processes including:

• RNA-mediated gene silencing through the RNA-induced silencing complex (RISC)

• mRNA metabolism and translation regulation

• Innate antiviral immunity via type I interferon production

• Inhibition of retrotransposition

• Regulation of synaptic transmission and neuronal development

The protein has a molecular weight of approximately 114 kDa, though it typically appears at 110-115 kDa in Western blots . MOV10's multifunctional nature makes it a critical target for research across virology, immunology, and neurodevelopmental studies.

What experimental applications are MOV10 antibodies commonly used for?

Based on extensive validation data, MOV10 antibodies are employed in multiple experimental techniques:

Note: Antibody performance is sample-dependent, and optimization is recommended for each experimental system .

How do I select the appropriate MOV10 antibody for my specific research application?

When selecting a MOV10 antibody, consider these critical factors:

• Target specificity: Determine which region of MOV10 your research requires. Options include:

  • N-terminal targeting antibodies (e.g., AA 1-310, AA 259-288)

  • C-terminal targeting antibodies

  • Full-length protein antibodies

• Host species and clonality: Available options include:

  • Rabbit polyclonal (most common)

  • Rabbit monoclonal (e.g., EPR14478)

  • Mouse monoclonal (e.g., 15C1B8)

• Cross-reactivity requirements: Some antibodies react with human samples only, while others cross-react with mouse, rat, and other species .

• Application compatibility: Verify validation data for your specific application (WB, IP, IHC, IF).

• Conjugation needs: Available as unconjugated or conjugated with:

  • Fluorescent dyes (e.g., CoraLite® Plus 488)

  • HRP for direct detection

  • Biotin for amplification systems

For retrotransposition studies or viral infection research, select antibodies validated in relevant experimental systems with demonstrated ability to detect protein interactions .

What are the optimal protocols for using MOV10 antibodies in Western blotting?

For optimal Western blot results with MOV10 antibodies:

Sample preparation:

• Lyse cells in RIPA buffer supplemented with protease inhibitors

• Sonicate briefly if nuclear MOV10 detection is required

• Centrifuge at 12,000g for 15 minutes at 4°C

• Quantify protein concentration (BCA or Bradford assay)

Gel electrophoresis and transfer:

• Load 20-50 μg total protein per lane

• Use 8% SDS-PAGE (MOV10 is a large protein ~114 kDa)

• Transfer to PVDF membrane (nitrocellulose is adequate but PVDF preferred)

• Confirm transfer efficiency with Ponceau S staining

Antibody incubation:

• Block membrane with 5% non-fat milk in TBST for 1 hour at room temperature

• Incubate with primary antibody (typically 1:2000-1:5000 dilution) overnight at 4°C

• Wash 3x with TBST, 5 minutes each

• Incubate with appropriate HRP-conjugated secondary antibody for 1 hour at room temperature

• Wash 4x with TBST, 5 minutes each

Expected results:

• MOV10 band should appear at approximately 110-115 kDa

• Include appropriate positive controls (HEK-293, HepG2, or HeLa cell lysates)

• Validate specificity using MOV10 knockdown/knockout samples

How can I effectively use MOV10 antibodies for co-immunoprecipitation studies?

Co-immunoprecipitation with MOV10 antibodies has been critical in identifying its interaction partners. To effectively perform Co-IP:

Protocol:

• Prepare cell lysates using mild lysis buffer (e.g., 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, protease inhibitors)

• Pre-clear lysate with protein A/G beads (30 minutes at 4°C)

• Incubate pre-cleared lysate with 2-5 μg MOV10 antibody overnight at 4°C

• Add protein A/G beads and incubate for 2 hours at 4°C

• Wash beads 4-5 times with wash buffer

• Elute proteins with sample buffer and analyze by Western blotting

Critical controls:

• Input sample (typically 5-10% of lysate used for IP)

• IgG control (same species as the MOV10 antibody)

• Reverse IP (IP with antibody against suspected interacting protein)

• RNase treatment controls to distinguish RNA-dependent vs. direct protein interactions

Studies have successfully used this approach to identify MOV10 interactions with:

• Viral proteins (coronavirus nucleocapsid protein)

• RNA-binding proteins (TIAR, AGO2, UPF1)

• Retrotransposon components (L1 ORF1p)

• Reverse transcriptases (both viral and retrotransposon)

What considerations are important when using MOV10 antibodies for immunofluorescence?

For successful immunofluorescence with MOV10 antibodies:

Sample preparation:

• Grow cells on coverslips to 70-80% confluence

• Fix with 4% paraformaldehyde (10 minutes at room temperature)

• Permeabilize with 0.1-0.2% Triton X-100 (5-10 minutes)

• Block with 5% BSA or normal serum in PBS (1 hour at room temperature)

Antibody incubation:

• Dilute primary antibody 1:50-1:500 in blocking buffer

• Incubate overnight at 4°C or 1-2 hours at room temperature

• Wash 3x with PBS

• Incubate with appropriate fluorescent-conjugated secondary antibody

• Include DAPI or Hoechst for nuclear staining

• Mount with anti-fade mounting medium

Expected results and validation:

• MOV10 typically shows cytoplasmic localization with some nuclear presence

• Diffuse and punctate staining patterns may be observed

• MOV10 localization can change during viral infection or stress

• Validate specificity using MOV10 knockdown/knockout controls

• Consider co-staining with markers for:

  • Stress granules (e.g., TIAR, G3BP)

  • P-bodies (e.g., DCP1a)

  • RISC components (e.g., AGO2)

How can MOV10 antibodies be used to study antiviral mechanisms?

MOV10 exhibits antiviral activity against multiple RNA viruses and some DNA viruses. To investigate these mechanisms:

Experimental approaches:

• Virus infection studies with MOV10 knockdown/overexpression:

  • Transfect cells with MOV10 expression constructs or siRNA/shRNA

  • Infect with virus (e.g., VSV, EMCV, HBV, coronaviruses)

  • Assess viral replication by plaque assay, qPCR, or Western blotting

  • Compare results between MOV10-modulated and control cells

• MOV10-viral protein interaction studies:

  • Perform co-immunoprecipitation with MOV10 antibodies after viral infection

  • Analyze precipitated viral proteins by Western blotting

  • Include RNase treatment controls to determine RNA-dependency

  • Example: MOV10 interaction with coronavirus nucleocapsid protein

• MOV10-viral RNA interaction analysis:

  • Conduct RNA immunoprecipitation (RIP) using MOV10 antibodies

  • Extract RNA from immunoprecipitates

  • Analyze viral RNA by RT-qPCR or sequencing

  • Example: MOV10 binding to HBV RNA

Key findings from published research:

• MOV10 enhances IRF3-mediated type I interferon induction

• MOV10 specifically requires IKKε for its antiviral activity against RNA viruses

• For HBV, MOV10 blocks reverse transcription without affecting viral gene expression

• For coronaviruses, MOV10 associates with viral nucleocapsid protein and may sequester viral RNA

What methodologies are effective for studying MOV10's role in retrotransposon inhibition?

MOV10 is a potent inhibitor of retrotransposition. To investigate this function:

Cell culture retrotransposition assays:

• Use reporter systems (e.g., neomycin-resistance cassettes in L1 constructs)

• Co-transfect with MOV10 expression vectors or knockdown reagents

• Measure retrotransposition frequency by colony formation or fluorescence

• Compare wild-type MOV10 with helicase-deficient mutants

MOV10-retrotransposon RNP interaction studies:

• Immunoprecipitate FLAG-tagged L1 constructs

• Detect co-precipitated MOV10 by Western blotting

• Include RNA-binding mutants as controls

• Test RNA-dependency by RNase treatment

• Reverse IP: use MOV10 antibodies to precipitate endogenous ORF1p

In vivo retrotransposition analysis:

• Generate MOV10 knockout or knockdown mouse models

• Use LINE1 reporter transgenes to measure retrotransposition events

• Compare heterozygous and homozygous models to assess gene dosage effects

• Examine both somatic and germline tissues

• Quantify LINE1 genomic content by exonuclease-treated DNA qPCR

Mechanistic investigations:

• In vitro reverse transcription inhibition assays

  • Incubate purified MOV10 with reverse transcriptase

  • Add target RNAs and measure cDNA synthesis

  • Compare MOV10 wild-type vs. helicase mutants

• Direct RT-binding studies

  • Couple RT to beads and assess MOV10 binding

  • Test N-terminal vs. C-terminal MOV10 fragments

  • Analyze MOV10 interaction with L1 ORF2p

What experimental designs are suitable for investigating MOV10's RNA-binding properties?

Understanding MOV10's RNA interactions is crucial for elucidating its functions:

High-throughput approaches:

• CLIP-seq/HITS-CLIP:

  • Cross-link RNA-protein complexes in vivo

  • Immunoprecipitate with MOV10 antibodies

  • Isolate RNA, construct libraries, and sequence

  • Analyze binding motifs and RNA types

  • Example: In P21 mouse testis, MOV10 was found to bind over 2300 transcripts, including retrotransposon RNAs

• RNA Immunoprecipitation (RIP):

  • Immunoprecipitate MOV10-RNA complexes without crosslinking

  • Extract RNA and analyze by RT-qPCR or sequencing

  • Examples: Detection of viral gRNA in MOV10 complexes from infected cells

Validation and focused approaches:

• UV crosslinking and RNA binding assays:

  • Use recombinant MOV10 or immunoprecipitated MOV10

  • Add labeled RNA probes

  • Analyze RNA binding by gel shift or filter binding assays

• RNA binding domain mapping:

  • Generate MOV10 domain constructs

  • Test RNA binding capabilities of different domains

  • Assess the role of the helicase domain in RNA recognition

• RNA binding specificity analysis:

  • Compare binding to different RNA types (viral, cellular, retrotransposon)

  • Identify sequence or structural motifs required for recognition

  • Test competition between different RNA targets

Relevant findings:

• MOV10 binds to 3' UTRs of mRNAs

• MOV10 recognizes retrotransposition-competent LINE1 transcripts

• MOV10 binds viral RNAs including HBV RNA and coronavirus gRNA

• RNA binding often depends on MOV10's helicase activity

How do I troubleshoot inconsistent results when using MOV10 antibodies?

When facing reproducibility issues with MOV10 antibodies:

Common problems and solutions:

• Inconsistent Western blot detection:

  • Problem: Weak or absent bands despite appropriate positive controls

  • Solutions:

    • Optimize protein extraction (use RIPA buffer with protease inhibitors)

    • Try longer transfer times (1-2 hours at lower voltage or overnight at 4°C)

    • Increase antibody concentration or incubation time

    • Use enhanced chemiluminescence substrate for higher sensitivity

    • Consider protein phosphorylation state (MOV10 can be phosphorylated)

• Non-specific bands in Western blots:

  • Problem: Multiple unexpected bands

  • Solutions:

    • Increase blocking time/concentration (5% milk for 2 hours)

    • Dilute antibody further (1:5000-1:10000)

    • Add 0.1% Tween-20 to antibody dilution buffer

    • Include MOV10 knockout/knockdown control

    • Try a different MOV10 antibody with alternative epitope targeting

• Failed co-immunoprecipitation:

  • Problem: Cannot detect known interaction partners

  • Solutions:

    • Use milder lysis conditions to preserve protein complexes

    • Include RNase controls (some interactions are RNA-dependent)

    • Add protease and phosphatase inhibitors freshly

    • Try reverse IP (immunoprecipitate the partner protein)

    • Cross-link proteins before lysis for transient interactions

• Weak immunofluorescence signal:

  • Problem: Dim or diffuse staining

  • Solutions:

    • Optimize fixation method (try methanol vs. paraformaldehyde)

    • Increase antibody concentration (start at 1:50 dilution)

    • Extend primary antibody incubation (overnight at 4°C)

    • Try antigen retrieval methods (for tissue sections)

    • Use signal amplification systems (e.g., biotin-streptavidin)

• Conflicting results with published data:

  • Problem: Results differ from literature reports

  • Solutions:

    • Verify cell type/tissue specificity (MOV10 functions can vary)

    • Check experimental conditions (stress, infection status)

    • Consider MOV10 isoforms or homologs (like MOV10b.1)

    • Validate antibody specificity in your experimental system

How can MOV10 antibodies be used to study neuronal development and function?

MOV10 plays critical roles in neuronal development as revealed by recent research:

Experimental strategies:

• Developmental expression analysis:

  • Perform Western blotting with MOV10 antibodies on brain extracts from different developmental stages

  • Use immunohistochemistry to map MOV10 expression in brain regions

  • Compare nuclear vs. cytoplasmic fractions during development

• MOV10's role in retrotransposon suppression in neurons:

  • Generate neuron-specific MOV10 knockout models

  • Measure L1 genomic content in neuronal DNA by qPCR

  • Perform RNA-seq to identify dysregulated retrotransposons

  • Use MOV10 antibodies for ChIP-seq to identify chromatin associations

• Synaptic function studies:

  • Perform subcellular fractionation to isolate synaptic components

  • Use MOV10 antibodies to detect MOV10 enrichment in synaptic fractions

  • Co-immunoprecipitate MOV10 with synaptic proteins

  • Analyze MOV10-associated mRNAs at synapses

Key research findings:

• MOV10 suppresses retroelements during early brain development

• MOV10 heterozygous knockout mice show increased LINE1 content in brain

• MOV10 directly inhibits reverse transcription in the developing brain

• MOV10 interacts with FMRP to regulate translation at synapses

• MOV10 is important for normal neuronal development and function

What is the significance of MOV10's helicase activity in its various cellular functions?

The helicase activity of MOV10 is critical for many of its functions:

Experimental approaches to study helicase function:

• Helicase activity assays:

  • Express and purify recombinant wild-type and helicase-mutant MOV10

  • Measure ATP-dependent RNA unwinding activity in vitro

  • Compare activities against different RNA substrates

• Functional comparison of wild-type vs. helicase mutants:

  • Generate helicase-dead mutants (e.g., K530A in motif I)

  • Express in cells and compare effects on:

    • Antiviral activity

    • Retrotransposition inhibition

    • mRNA regulation

    • Protein interactions

  • Use MOV10 antibodies to ensure equivalent expression levels

• RNA structure analysis:

  • Immunoprecipitate MOV10-bound RNAs

  • Compare structural changes in bound vs. unbound RNAs

  • Analyze impact of MOV10's helicase activity on RNA secondary structures

Research findings on helicase function:

• Helicase-deficient MOV10 fails to suppress HBV replication

• The helicase function is required to block retrotransposon reverse transcription

• MOV10 uses its helicase activity to counteract HIV-1 Vif-mediated degradation of APOBEC3G

• The helicase domain is necessary for proper MOV10 localization in RNA granules

• MOV10 requires helicase activity to promote miRNA-mediated gene silencing

How do MOV10 knockout/knockdown models contribute to understanding its physiological roles?

MOV10 knockout and knockdown models provide critical insights into its in vivo functions:

Key experimental approaches:

• Cellular knockout/knockdown systems:

  • Generate CRISPR/Cas9-mediated MOV10 knockout cell lines

  • Use siRNA or shRNA for transient knockdown

  • Verify knockdown efficiency using MOV10 antibodies

  • Examine effects on viral replication, retrotransposition, and gene expression

• Mouse knockout models:

  • Generate complete or conditional MOV10 knockout mice

  • Study embryonic lethality phenotypes (incomplete penetrance reported)

  • Analyze tissue-specific effects in surviving knockouts

  • Use LINE1 reporter transgenes to measure retrotransposition rates

• Rescue experiments:

  • Reintroduce wild-type or mutant MOV10 into knockout systems

  • Test domain-specific contributions to function

  • Examine gene dosage effects using heterozygous models

Key findings from knockout studies:

• MOV10 knockout causes partial embryonic lethality in mice

• Surviving MOV10-deficient mice appear grossly normal and are fertile

• MOV10 inhibits LINE1 retrotransposition in both somatic and reproductive tissues in a gene dosage-dependent manner

• MOV10 knockout alters the transcriptome in testis

• MOV10 forms a complex with UPF1 in testis tissues

• Loss of MOV10 increases LINE1 retrotransposition in both embryonic and adult tissues

This data has established MOV10 as a bona fide host restriction factor for retrotransposons and viruses in vivo, with critical roles in embryonic development.

What are the key differences between monoclonal and polyclonal MOV10 antibodies?

Understanding the distinctions between antibody types is crucial for experimental design:

Polyclonal MOV10 antibodies:

• Advantages:

  • Recognize multiple epitopes on MOV10

  • Higher sensitivity for detection

  • More tolerant of protein denaturation/modifications

  • Generally work well across multiple applications

• Limitations:

  • Batch-to-batch variation

  • May show cross-reactivity with related proteins

  • Less specific than monoclonals

• Common applications: WB, IP, IHC, IF

• Examples: ABIN1680885, 10370-1-AP

Monoclonal MOV10 antibodies:

• Advantages:

  • Consistent epitope recognition

  • Higher specificity

  • Less background in some applications

  • Better for quantitative analyses

• Limitations:

  • May be sensitive to epitope modifications

  • Sometimes less sensitive than polyclonals

  • May be more application-restricted

• Common applications: WB, IP, IHC, IF

• Examples: 15C1B8 (mouse monoclonal), EPR14478 (rabbit monoclonal)

Application-specific recommendations:

• For detecting potentially modified MOV10: Use polyclonal antibodies

• For highly specific detection: Use monoclonal antibodies

• For immunoprecipitation of complexes: Test both types, as epitope accessibility may differ

• For reproducible quantitative analysis: Prefer monoclonal antibodies

• For detecting MOV10 across species: Verify cross-reactivity of each antibody

What controls are essential when using MOV10 antibodies for various applications?

Proper controls are critical for reliable MOV10 antibody experiments:

Essential controls for Western blotting:

• Positive control lysate (HEK-293, HepG2, or HeLa cells)

• MOV10 knockdown/knockout negative control

• Loading control (e.g., GAPDH, β-actin, tubulin)

• Molecular weight marker to confirm expected size (110-115 kDa)

Essential controls for immunoprecipitation:

• Input sample (5-10% of lysate used for IP)

• IgG control from same species as MOV10 antibody

• MOV10 knockout/knockdown control

• RNase treatment control if studying RNA-dependent interactions

• Beads-only control (no antibody)

Essential controls for immunofluorescence:

• MOV10 knockout/knockdown cells

• Secondary antibody-only control

• Preimmune serum or isotype-matched IgG control

• Peptide competition control (where antibody is pre-incubated with immunizing peptide)

Essential controls for RNA immunoprecipitation:

• Input RNA sample

• IgG control IP

• MOV10 knockout/knockdown control

• DNase treatment control

• RT-negative control for qPCR analysis

Essential controls for viral/retrotransposon studies:

• MOV10 wild-type vs. helicase-deficient mutant comparison

• Empty vector control for overexpression studies

• Non-targeting siRNA/shRNA for knockdown studies

• Dose-response analysis for MOV10 expression levels

What experimental considerations are important when studying MOV10 in different species?

When conducting comparative MOV10 research across species:

Cross-reactivity verification:

• Test each antibody against lysates from multiple species

• Verify expected molecular weight differences between species

• Include appropriate positive controls for each species

• Consider species-specific antibodies for critical experiments

Species-specific MOV10 characteristics:

• Human MOV10:

  • 114 kDa protein, broadly expressed

  • Well-characterized in antiviral and retrotransposon studies

  • Multiple validated antibodies available

• Mouse MOV10:

  • Important in brain development studies

  • Forms complex with UPF1 in testis

  • Critical for embryonic viability (partial penetrance)

  • Knockout mice display increased L1 retrotransposition

• Rat MOV10:

  • Less extensively studied

  • Verify antibody cross-reactivity before use

  • Several antibodies validated for rat samples

Experimental design considerations:

• For evolutionary studies:

  • Use species-specific primers for qPCR

  • Consider codon optimization for expression constructs

  • Analyze sequence conservation in functional domains

• For developmental studies:

  • Account for species-specific developmental timelines

  • Consider tissue-specific expression differences

  • Use age-matched samples for comparative studies

• For functional comparisons:

  • Test activity in species-matched cell lines when possible

  • Consider using species-specific viral or retrotransposon targets

  • Account for potential differences in protein interaction networks

How is MOV10 involved in the regulation of microRNA-mediated gene silencing?

Recent studies have revealed MOV10's important role in microRNA pathways:

Key methodological approaches:

• MOV10-AGO2 interaction studies:

  • Immunoprecipitate MOV10 and detect AGO2 co-precipitation

  • Perform reverse IP with AGO2 antibodies

  • Test RNA-dependency of interactions

  • Analyze effects of MOV10 knockdown on AGO2-associated miRNAs

• miRNA activity assays:

  • Use luciferase reporters with miRNA target sites

  • Compare activity in MOV10 wild-type vs. knockout/knockdown cells

  • Test helicase-deficient MOV10 mutants

  • Analyze impact of MOV10 on both translational repression and target cleavage

• MOV10-RISC component interactions:

  • Study associations with other RISC proteins

  • Investigate MOV10-FMRP interactions in miRNA regulation

  • Analyze RNA structural changes facilitated by MOV10

Research findings:

• MOV10 is required for both miRNA-mediated translational repression and miRNA-mediated cleavage of complementary mRNAs by RISC

• MOV10 cooperates with FMRP to regulate miRNA-mediated translational repression by AGO2

• MOV10 may facilitate miRNA-target interactions by unwinding RNA secondary structures

• MOV10 contributes to UPF1 mRNA target degradation by translocation along 3' UTRs

These findings establish MOV10 as a critical component of the miRNA machinery, particularly in the context of neuronal development and function.

What are the latest findings on MOV10's role in coronavirus infections?

Recent research has illuminated MOV10's interactions with coronaviruses:

Experimental approaches:

• MOV10-coronavirus protein interaction studies:

  • Immunoprecipitate MOV10 from coronavirus-infected cells

  • Detect co-precipitation of viral proteins (particularly nucleocapsid)

  • Perform reverse IPs with antibodies against viral proteins

  • Include RNase treatments to determine RNA-dependency

• MOV10 antiviral activity assessment:

  • Generate MOV10 knockout/knockdown cell lines

  • Infect with coronaviruses (MERS-CoV used as model)

  • Measure viral RNA, protein levels, and viral titers

  • Compare wild-type vs. helicase-deficient MOV10

• MOV10-coronavirus RNA interaction analysis:

  • Perform RNA immunoprecipitation with MOV10 antibodies

  • Quantify viral RNA in immunoprecipitates by RT-qPCR

  • Compare with negative control immunoprecipitations

  • Analyze impact on viral RNA stability and translation

Key findings:

These findings suggest MOV10 may sequester viral RNAs into cytoplasmic ribonucleoprotein structures to limit viral protein production, representing a novel antiviral mechanism.

How does MOV10 cooperate with other cellular factors to restrict retrotransposition?

Recent studies have identified key MOV10 partnerships in retrotransposon control:

Experimental approaches:

• MOV10-UPF1 interaction studies:

  • Immunoprecipitate MOV10 from testicular extracts

  • Identify UPF1 as associated protein by mass spectrometry

  • Confirm association by co-immunoprecipitation and Western blot

  • Analyze functional consequences on retrotransposon control

• MOV10 cooperation with terminal uridyltransferases:

  • Study interaction with TUT4 and TUT7

  • Analyze uridylation of LINE1 mRNAs

  • Test impact on LINE1 RNA stability and reverse transcription

  • Compare effects of individual vs. combined knockdowns

• MOV10-RNASEH2 functional interactions:

  • Analyze MOV10 dependency of RNASEH2 activity

  • Study hydrolysis of LINE1-specific RNA-DNA hybrids

  • Investigate nuclear vs. cytoplasmic activities

  • Examine direct protein-protein interactions

Key findings:

• MOV10 forms a complex with UPF1 (a key nonsense-mediated decay component) in mouse testis

• MOV10 cooperates with terminal uridyltransferases TUT4 and TUT7 to promote uridylation of LINE1 mRNA

• This uridylation destabilizes LINE1 mRNA and inhibits its reverse transcription

• MOV10 facilitates LINE1 uridylation by TUT4 and TUT7

• MOV10 interacts with RNASEH2, which hydrolyzes LINE1-specific RNA-DNA hybrids in a MOV10-dependent manner

• MOV10 counteracts the RNA chaperone activity of L1RE1